Novartis AG (NVS)
| Previous close | 84.17 |
| Open | 84.85 |
| Bid | 84.93 x 1300 |
| Ask | 84.92 x 800 |
| Day's range | 84.66 - 85.12 |
| 52-week range | 79.09 - 95.17 |
| Volume | |
| Avg. volume | 2,460,800 |
| Market cap | 189.501B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 7.92 |
| EPS (TTM) | 10.73 |
| Earnings date | N/A |
| Forward dividend & yield | 3.33 (4.10%) |
| Ex-dividend date | 08 Mar 2022 |
| 1y target est | 104.40 |
- Reuters
Novartis to cut up to 8,000 jobs globally
ZURICH (Reuters) -Novartis said on Tuesday a previously announced restructuring programme could lead to 8,000 jobs being cut, or about 7.4% of its global workforce, including up to 1,400 in Switzerland. The job cuts, previously projected by Chief Executive Vas Narasimhan to be in the "single digit thousands", are part of a restructuring programme the Swiss pharmaceutical group announced in April, targeting savings of at least $1 billion by 2024. Novartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating its pharmaceuticals and oncology business units and would lead to eliminating roles across the organisation.
- Zacks
Q2 Earnings Season Preview and Featured Analyst Reports for J&J, AMD & Union Pacific
Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).
- Zacks
Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML
The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.
